A Brief
Depression is largely seen by the general public and the mainstream media as a neuropsychiatric illness, with a fluctuating course, which can be best described in disease-state terms such as disorder, episodes, remission, recovery, relapse, and recurrence. MDD is among the most frequent and severe psychiatric conditions, affecting about 15 % of the global population. Although it is the second most important cause of worldwide disability, the neuropathology of depression remains largely unknown.
Common antidepressants work through the monoamine hypothesis of depression, but are not effective against all types of MD. Another hypothesis, blocking N-methyl D-aspartate (NMDA) receptors (NMDAR) with antagonists to promote antidepressant effects, hasn’t been very useful because of the adverse side effects of the NMDA antagonists. We suggest that these side effects can be significantly reduced through a specific drug delivery process using nanocarriers. Using a computer aided molecular model of a hollow spherical polypyrrole nanocarrier potent NMDAR antagonists R-ketamine are introduced in the neuronal environment of the central nervous system (CNS) through intranasal route. It is observed that the nanocarrier ruptures and releases the drug in response to membrane potential conditions associated with MDD and that the released R-ketamine has high binding affinity for NMDAR. The results of this in silico experiment need to be further explored in an in vivo pharmacological study.
Get in Touch
Up for all kinds of collaborations which can take us close to understanding human brain. Comfortable with all kinds of BioInformatic softwares. Further experienced in developing efficient AI Models, with decent Accuracy. Can also contact me to get more detailed information regarding any of my work over the site.
veb7vmehra@gmail.com